A study published in the Journal of Thoracic Oncology suggested that the adoption of molecular testing for lung cancer is globally relatively low due to barriers including cost, access, quality, turn-around time, and lack of awareness.1
Given these findings, researchers indicated that continuous education around molecular testing in lung cancer should be intensified on both national and international levels to ensure patients receive optimal therapy.
“The landscape of molecular testing is complex and rapidly evolving, highlighting the need for regular updates to expert statements and guidelines,” the authors wrote. “Many of the barriers identified can be address with improved awareness and standardization of processes.”
In order to address the knowledge gap, the International Association for the Study of Lung Cancer (IASLC) conducted an international survey to assess…